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Objective. To evaluate the cutaneous and the inner ear tolerance of bioactive glass S53P4 when used in themastoid and epitympanic
obliteration for chronic otitis surgery. Material and Methods. Forty-one cases have been included in this prospective study.
Cutaneous tolerance was clinically evaluated 1 week, 1 month, and 3 months after surgery with a physical examination of the
retroauricular and external auditory canal (EAC) skin and the presence of otalgia; the inner ear tolerance was assessed by bone-
conduction hearing threshold 1 day after surgery and by the presence of vertigo or imbalance. Results. All surgeries but 1 were
uneventful: all patients maintained the preoperative bone-conduction hearing threshold except for one case in which the round
window membrane was opened during the dissection of the cholesteatoma in the hypotympanum and this led to a dead ear. No
dizziness or vertigo was reported. Three months after surgery, healing was achieved in all cases with a healthy painless skin. No
cases of revision surgery for removal of the granules occurred in this study.Conclusion. The bioactive glass S53P4 is a well-tolerated
biomaterial for primary or revision chronic otitis surgery, as shown by the local skin reaction which lasted less than 3 months and
by the absence of labyrinthine complications.
1. Introduction
Bioactive glass S53P4 (BG) is a bioactive material that elicits
a specific biological response at the interface of material and
tissue resulting in the formation of a bond between them [1].
It is a silica-based biomaterial with bone bonding properties
[2, 3], osteoconductive and osteoproductive in promoting
migration, replication, and differentiation of osteogenic cells
[4, 5]. The material is a mixture of oxides composed by
53% SiO
2
, 23% Na
2
O, 20% CaO, and 4% P
2
O
5
. After the
interaction with body fluids, the rapid ions exchange forms
a Si-rich layer that interacts with Ca2+ and PO4
3− to allow the
crystallization of hydroxyl carbonate apatite over the surface
of the granules [6]. Together with this chemical mechanism,
a cellular mechanism promotes osteostimulation and new
bone formation: the bioactive glass stimulates the growth and
maturation of osteoblasts and promotes the maintenance of
osteoblastic phenotype [7, 8] that produces the bone matrix
guided by the hydroxyapatite layer formed over the granule’s
surface. Studies in vivo demonstrated that when implanted
in a cavity created in the tibia of rats in contact with bone
marrow, it promotes the new bone formation and, 8 weeks
after implantation, animals implantedwith BGhad 50%more
bone formation than the control group [9, 10].
Furthermore, the BG has the unique property of being
antibacterial over many aerobic and anaerobic bacteria [11,
12]. The inhibition of bacterial growth is probably due to the
release of ions at the first stage of implantation which causes
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elevation of the pH and of the osmotic pressure. Moreover,
the BG can suppress Staphylococcus aureus and Pseudomonas
aeruginosa biofilms formation on titanium alloy disc in vitro
[13, 14].
Clinical studies regarding the use of BG have been
published in orthopedic (trauma [15, 16], benign bone tumors
[17], and chronic osteomyelitis [18, 19] surgeries) and cranio-
facial (frontal [20, 21], maxillary [22] sinus surgery) fields.
Few reports have been published in ear surgery concern-
ing the rehabilitation of canal-wall-down mastoidectomies
[23–25]. Unlike long bones, themastoid bone contains cells in
contact with air.Themastoid cavities are covered bymodified
respiratory epithelium with ciliated and secretory cells and
the bone does not contain bone marrow. Moreover, the
mastoid cavities are in direct contact with the inner ear that
contains auditory and vestibular hair cells whose functioning
is dependent of inner ear fluids ionic composition [26–28].
The aim of this prospective observational uncontrolled
study was to assess the cutaneous (retroauricular and the
external auditory canal) and inner ear tolerance of the BG
S53P4when used for obliteration of canal-wall-down (CWD)
and canal-wall-up (CWU) mastoidectomies.
2. Material and Methods
This study, carried out between May 2013 and January 2015,
was authorized by the ethical institutional board, and all
patients gave their written consents for the use of their
personal clinical data. The bioactive glass S53P4 is produced
by BonAlive Biomaterials Ltd. (Turku, Finland) and has been
approved for clinical use in 2004 in Europe and in 2007 in the
United States.
The tolerance of the material was clinically evaluated for
the skin of the retroauricular and external auditory canal
(EAC) 1 week, 1 month, and 3 months after surgery with
physical examination and otoscopy under microscope. The
presence of pain was also evaluated during the same exam-
ination. The presence of otorrhea and infection was also
investigated.
Inner ear tolerance was evaluated clinically with the pres-
ence of vertigo and/or dizziness and with bone-conductive
pure-tone audiometry performed one day after surgery.
Forty-one cases (39 patients, two operated bilaterally)
were included: there were 22 males and 17 females.The mean
age was 46 ± 15 years (mean ± SD, range 16–79 years).
There were 25 right side and 16 left side cases. The mean
preoperative bone-conduction hearing threshold calculated
at 0.5, 1, 2, and 3 kHz was 32 ± 17.2 dB.
All patients were operated on general anesthesia with
facial nerve monitoring system NIM-Response 2 and NIM-
Response 3 (Medtronic, Jacksonville, FL, USA). After bacte-
riological sampling collected with a swab in the EAC and/or
in the mastoid cavity, a retroauricular skin incision and a
C-shaped muscoloperiosteal flap were performed. Fibrous
tissue (temporalis fascia, retroauricular fibrous tissue, peri-
chondrium, and pericranium) was harvested. Cartilages
from cymba, cavum conchae, and tragus were sampled and
thinned using Precise Cartilage Knife (Kurz, Tuebingen, Ger-
many). Afterwards primary (𝑛 = 10) or revision (𝑛 = 25)
Table 1: Results of perioperative bacteriological test (𝑛 = 41).
BACTERIA 𝑁
Aseptic 18
Staphylococcus 8
(i) aureus (𝑛 = 4)
(ii) Coagulase negative (𝑛 = 2)
(iii) Epidermidis (𝑛 = 1)
(iv) Association (𝑛 = 1)
Pseudomonas aeruginosa 3
Candida 2
(i) albicans (𝑛 = 1)
(ii) parapsilosis (𝑛 = 1)
Streptococcussanguinis 1
Stenotrophomonas maltophilia 1
Propionibacterium sp. 1
Turicella otitidis 1
Proteus mirabilis 1
Aspergillus niger 1
Association of bacteria 4
CWD or CWU (𝑛 = 6) mastoidectomy was performed. A
cholesteatoma was found in 23 cases. After the removal of
the lesion, the reconstruction started with the middle ear
(tympanic drum grafting and ossiculoplasty) and was fol-
lowed by mastoid and epitympanic obliteration using the
BG granules (size 0.5/08mm) previously moistened with 3
cc of saline solution. The granules were carefully covered
by cartilage and fibrous tissue in the reconstructed EAC
(Figure 1), and particular attention was taken to ensure that
the reconstructed EAC reached the level of the lateral skin of
the meatoplasty.Then, the reconstructed EAC was filled with
MeroGel ear packing (Medtronic, Jacksonville, FL, USA).
Perioperative antibioprophylaxis with amoxicillin/clavu-
lanate was performed in all patients and it was continued
until it has been adapted to the results of the periopera-
tive bacteriological test. The treatment was delivered for 14
days following recommendations for chronic otitis [29] and
cochlear implant surgeries [30] with mastoid obliteration.
Ear drops of ofloxacin were administered to all patients for
1 month.
3. Results
All the mastoid cavities and epitympanic spaces were filled
with a volume of granules between 4 and 5 cc. In all the
cases, cartilage and fibrous tissue were enough to allow a
complete covering of the exposed granules in the EAC even
in multioperated ears; there was no need to perform a mus-
coloperiostal flap to cover the granules.
Results of bacteriological test are shown in Table 1. In
23 cases (56%) bacteria or fungus was found, sometimes in
association (𝑛 = 5).
All but 1 patient conserved the preoperative bone-
conductive hearing threshold; this patient had an opening
of the round window membrane during the dissection of
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Figure 1: Surgical view of left ear after reconstruction of the external auditory canal andmastoid obliteration with bioactive glass granules. (a)
After reconstruction of middle ear in a canal-wall-down mastoidectomy; (b) after positioning of the granules; (c) at the end of the procedure
before skin closure: note the mastoid completely obliterated by the granules (black oval) covered by cartilage (black stars).
the cholesteatoma in the hypotympanum and experienced
ipsilateral total hearing loss postoperatively. Contrariwise,
three cases of preoperative lateral semicircular canal fistulas,
where an opening of the posterior labyrinth occurred dur-
ing surgery, maintained the preoperative bone-conduction
hearing threshold. Postoperative bone-conductive hearing
threshold was 28 ± 18.4 dB (𝑛 = 40, deaf patient excluded).
Seven days after surgery, the retroauricular skin was
healthy in all patients but 1; the latter experienced retroauric-
ular swelling without inflammation of the skin and moderate
aseptic otorrhea; this patient was treated conservatively.
Five patients (12%) complained of otalgia without any
sign of inflammation. No vertigo or dizziness was reported
by patients.
One month after surgery, retroauricular skin was healthy
in all patients. Skin of the EAC showed somedegree of inflam-
mation with swelling of the posterior wall in 13 cases (32%).
All cases were successfully treated with the positioning of an
ear pop wick and administration of ear drops (association
of antibiotics and corticosteroid) for 14 days. One patient
experienced purulent otorrhea due to Pseudomonas aerugi-
nosa infection that was successfully treated with intravenous
ceftazidime for 14 days. One patient presented uncovered
granules in the EAC due to cartilage resorption: this patient
underwent revision surgery under local anesthesia to cover
the exposed granules in the EAC two months after the
primary surgery.
Three months after surgery, healing was achieved in all
patients. No cases of retroauricular or EAC skin inflamma-
tion were reported, with a healthy skin in the retroauricular
and EAC examination (Figure 2).
4. Discussion
The use of biocompatible materials has been reported for
many years in otologic surgery. In this field, especially in revi-
sion surgeries and/or in multioperated ears, the availability
of autologous materials could be a challenge for the otologic
surgeon.Moreover, the possibility of the donor-sitemorbidity
and the risk of resorption over time should be kept in mind
when choosing them for reconstruction. This is why a lot of
reports in the literature described the use of biocompatible
materials either in ossicular chain replacement prosthesis
and/or mastoid obliteration, with excellent results.
Regarding mastoid obliteration, either autologous mate-
rials (muscular flap [31], bone [32], bone pate [33], cartilage
[34], and fat [35]) or biocompatible materials (silicon blocks
[36], hydroxyapatite cement [37], and titanium posterior wall
prosthesis [38]) have been already described.
The BG is a bone-substitute material that allows the
restoration of bone stock by resorption and further apposi-
tion of new bone from a differentiated tissue.
In the orthopedic field, other bone-substitute mate-
rials such as bioresorbable bioactive ceramics (calcium
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Figure 2: Preoperative (a) and postoperative (b) physical examination and postoperative otoscopy (c) of a patient operated for the obliteration
of a canal-wall-down mastoidectomy with BonAlive granules, 3 months after surgery.
phosphates, hydroxyapatite, and tricalcium phosphate) are
most commonly used as osteoconductive bone graft sub-
stitute [39, 40]. The main differences between these bone
substitutes have already been described [6].
In ear surgery, the use of biphasic ceramic (BC), a mix-
ture of hydroxyapatite and tricalcium phosphate with fibrin
sealant, has been described by some authors for the rehabili-
tation of CWDmastoidectomies [29, 41–43]. However, some
cases of infection of the implanted material and subsequent
revision surgery in order to remove the granules have been
reported.
WeusedBCas an obliteratingmaterial for the obliteration
of the mastoid and epitympanic cavities from 2006 to 2013 in
130 cases. Our results on the first 59 cases with a minimum
follow-up of 1 year were retrospectively reviewed [29]. The
same surgical technique as well as the same antibiotherapy
was applied in this prospective study using the BG. From
a surgical point of view, the BG is easier to manage than
BC with fibrin sealant, since with the latter positioning of
the granules in the mastoid cavity should be performed
within 10 minutes following the preparation. Furthermore,
the granules of BC are larger than the granules of BG and this
makes the obliteration of smaller spaces (as e.g., the anterior
epitympanum) more difficult.
Regarding the cutaneous tolerance, in our series, BC
granules were removed because of infection or pain in 4
patients. These complications occurred early in the postop-
erative period. Conversely, no case of revision surgery for
removal of granules with the use of BG has been observed in
the present study. With the surgical technique, the surgeons,
and the antibiotherapy being the same in the two studies, this
difference might be due to the antibacterial property of the
BG: indeed, the results of our preoperative bacteriological
tests showed that all the bacteria we found were sensitive to
the BG mechanism of action in vitro [11, 12, 14]. Moreover,
even in case of fungus infection, we did not observe any
infection of the implanted material even if the BG properties
have not been tested yet against fungus in vitro.
Furthermore, we wondered about the inner ear tolerance
of the BG. Because of the increase of pH and osmotic pressure
in the hour following the placement of the granules, it was
proved that this material does not have adverse side effects
on the labyrinthine structures. All but one patientmaintained
the preoperative bone-conduction threshold, and no patient
complained of vertigo even in case of opening of the posterior
labyrinth during the dissection of the cholesteatoma. The
only patient that experienced immediate postoperative sen-
sorineural hearing loss underwent the opening of the round
windowmembrane during the surgery, and hence the hearing
loss can be attributed to the surgical procedure rather than an
inner ear toxicity.
The first report on the use of BG S53P4 BonAlive in ear
surgery was realized by Stoor et al. [23]; they retrospectively
reviewed 7 patients treated for mastoid obliteration with
BG and they focused only on the size of postoperative
cavities without any concern about the inner ear tolerance.
Similarly, Silvola [24], in a prospective study carried out on
14 patients, did not observe any infection of the granules
and described a good skin tolerance. But Sarin et al. [25],
on a retrospective study on 26 patients treated over a 25-
year period, experienced 2 cases of recurrent postoperative
otorrhea, 1 case of opened wound, 1 case of exposed BG
granules in the EAC, and 1 case of profound deafness, but
no statement was made concerning the cause of this hearing
loss.
In the present study, we did not observe any adverse
reaction toBGgranules; only one patient had to be reoperated
because there were uncovered BG granules in the EAC one
month after surgery. However, this also occurred with the
use of BC in a larger percentage of patients, suggesting an
incomplete recovering of the granules rather than an adverse
effect of the biomaterial. In our opinion, attentive coverage
of the granules with cartilage is essential and mandatory.
As already reported [24], fibrous tissue is not enough and
this could expose the implanted material to infection and/or
extrusion.
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In conclusion, this prospective study focused on the tol-
erance of BG demonstrated that the BG S53P4 is a very well-
tolerated material for mastoid and epitympanic obliteration.
Anatomical and functional results need to be evaluated in a
longer follow-up period.
Conflict of Interests
The authors do not have any conflict of interests or financial
disclosure to declare.
References
[1] L. L. Hench and O. H. Andersson,An Introduction to Bioceram-
ics, World Scientific, 1993.
[2] L. L.Hench and J.Wilson, “Surface-active biomaterials,” Science,
vol. 226, no. 4675, pp. 630–636, 1984.
[3] P. Ducheyne and Q. Qiu, “Bioactive ceramics: the effect of
surface reactivity on bone formation and bone cell function,”
Biomaterials, vol. 20, no. 23-24, pp. 2287–2303, 1999.
[4] P. Virolainen, J. Heikkila¨, A. Yli-Urpo, E. Vuorio, and H. T.
Aro, “Histomorphometric and molecular biologic comparison
of bioactive glass granules and autogenous bone grafts in
augmentation of bone defect healing,” Journal of Biomedical
Materials Research, vol. 35, no. 1, pp. 9–17, 1997.
[5] O. H. Andersson, G. Liu, K. Kangasniemi, and J. Juhanoja,
“Evaluation of the acceptance of glass in bone,” Journal of
Materials Science: Materials in Medicine, vol. 3, no. 2, pp. 145–
150, 1992.
[6] V.-V. Va¨lima¨ki and H. T. Aro, “Molecular basis for action of
bioactive glasses as bone graft substitute,” Scandinavian Journal
of Surgery, vol. 95, no. 2, pp. 95–102, 2006.
[7] I. D. Xynos, M. V. J. Hukkanen, J. J. Batten, L. D. Buttery, L.
L. Hench, and J. M. Polak, “Bioglass 45S5 stimulates osteoblast
turnover and enhances bone formation in vitro: implications
and applications for bone tissue engineering,” Calcified Tissue
International, vol. 67, no. 4, pp. 321–329, 2000.
[8] M. Bosetti and M. Cannas, “The effect of bioactive glasses on
bonemarrow stromal cells differentiation,”Biomaterials, vol. 26,
no. 18, pp. 3873–3879, 2005.
[9] V.-V. Va¨lima¨ki, J. J. Yrjans, E. I. Vuorio, and H. T. Aro, “Molec-
ular biological evaluation of bioactive glass microspheres and
adjunct bone morphogenetic protein 2 gene transfer in the
enhancement of new bone formation,” Tissue Engineering, vol.
11, no. 3-4, pp. 387–394, 2005.
[10] V.-V. Va¨lima¨ki, J. J. Yrjans, E. Vuorio, andH. T. Aro, “Combined
effect of BMP-2 gene transfer and bioactive glass microspheres
on enhancement of new bone formation,” Journal of Biomedical
Materials Research—Part A, vol. 75, no. 3, pp. 501–509, 2005.
[11] O. Leppa¨ranta, M. Vaahtio, T. Peltola et al., “Antibacterial effect
of bioactive glasses on clinically important anaerobic bacteria in
vitro,” Journal ofMaterials Science:Materials inMedicine, vol. 19,
no. 2, pp. 547–551, 2008.
[12] E.Munukka, O. Leppa¨ranta,M. Korkeama¨ki et al., “Bactericidal
effects of bioactive glasses on clinically important aerobic
bacteria,” Journal of Materials Science: Materials in Medicine,
vol. 19, no. 1, pp. 27–32, 2008.
[13] D. C. Corac¸a-Huber, M. Fille, J. Hausdorfer, D. Putzer, and M.
Nogler, “Efficacy of antibacterial bioactive glass S53P4 against
S. aureus biofilms grown on titanium discs in vitro,” Journal of
Orthopaedic Research, vol. 32, no. 1, pp. 175–177, 2014.
[14] L. Drago, C. Vassena, S. Fenu et al., “In vitro antibiofilm activity
of bioactive glass S53P4,” Future Microbiology, vol. 9, no. 5, pp.
593–601, 2014.
[15] K. Pernaa, I. Koski, K. Mattila et al., “Bioactive glass S53P4 and
autograft bone in treatment of depressed tibial plateau fractures:
a prospective randomized 11-year follow-up,” Journal of Long-
Term Effects of Medical Implants, vol. 21, no. 2, pp. 139–148, 2011.
[16] J. Rantakokko, J. P. Frantze´n, J. Heina¨nen et al., “Posterolateral
spondylodesis using bioactive glass S53P4 and autogenous
bone in instrumented unstable lumbar spine burst fractures. A
prospective 10-year follow-up study,” Scandinavian Journal of
Surgery, vol. 101, no. 1, pp. 66–71, 2012.
[17] N. C. Lindfors, J. T. Heikkila¨, I. Koski, K. Mattila, and A.
J. Aho, “Bioactive glass and autogenous bone as bone graft
substitutes in benign bone tumors,” Journal of Biomedical
Materials Research—Part B Applied Biomaterials, vol. 90, no. 1,
pp. 131–136, 2009.
[18] C. L. Romano`, N. Logoluso, E. Meani et al., “A comparative
study of the use of bioactive glass S53P4 and antibiotic-loaded
calcium-based bone substitutes in the treatment of chronic
osteomyelitis: a retrospective comparative study,” The Bone &
Joint Journal, vol. 96, no. 6, pp. 845–850, 2014.
[19] J. McAndrew, C. Efrimescu, E. Sheehan, and D. Niall, “Through
the looking glass; Bioactive glass S53P4 (BonAlive) in the
treatment of chronic osteomyelitis,” Irish Journal of Medical
Science, vol. 182, no. 3, pp. 509–511, 2013.
[20] M. Peltola, J. Suonpa¨a¨, K. Aitasalo,M. Varpula, A. Yli-Urpo, and
R.-P. Happonen, “Obliteration of the frontal sinus cavity with
bioactive glass,”Head and Neck, vol. 20, no. 4, pp. 315–319, 1998.
[21] M. Peltola, K. Aitasalo, J. Suonpa¨a¨,M. Varpula, andA. Yli-Urpo,
“Bioactive glass S53P4 in frontal sinus obliteration: a long-term
clinical experience,” Head and Neck, vol. 28, no. 9, pp. 834–841,
2006.
[22] T. Turunen, J. Peltola, A. Yli-Urpo, and R.-P. Happonen, “Bioac-
tive glass granules as a bone adjunctive material in maxillary
sinus floor augmentation,” Clinical Oral Implants Research, vol.
15, no. 2, pp. 135–141, 2004.
[23] P. Stoor, J. Pulkkinen, and R. Gre´nman, “Bioactive glass S53P4
in the filling of cavities in the mastoid cell area in surgery
for chronic otitis media,” Annals of Otology, Rhinology and
Laryngology, vol. 119, no. 6, pp. 377–382, 2010.
[24] J. T. Silvola, “Mastoidectomy cavity obliteration with bioactive
glass: a pilot study,” Otolaryngology—Head and Neck Surgery,
vol. 147, no. 1, pp. 119–126, 2012.
[25] J. Sarin, R. Gre´nman, K. Aitasalo, and J. Pulkkinen, “Bioactive
glass S53P4 in mastoid obliteration surgery for chronic otitis
media and cerebrospinal fluid leakage,” Annals of Otology,
Rhinology & Laryngology, vol. 121, no. 9, pp. 563–569, 2012.
[26] V. Couloigner, O. Sterkers, and E. Ferrary, “What’s new in ion
transports in the cochlea?” Pflugers Archiv European Journal of
Physiology, vol. 453, no. 1, pp. 11–22, 2006.
[27] V. Couloigner, O. Sterkers, and E. Ferrary, “Na transport in the
cochlea of mammals,” Ne´phrologie, vol. 23, no. 6, pp. 245–247,
2002.
[28] L. Chelikh,M. Teixeira, C.Martin, O. Sterkers, E. Ferrary, andV.
Couloigner, “High variability of perilymphatic entry of neutral
molecules through the roundwindow,”ActaOto-Laryngologica,
vol. 123, no. 2, pp. 199–202, 2003.
[29] D. Bernardeschi, Y. Nguyen, I. Mosnier, M. Smail, E. Ferrary,
and O. Sterkers, “Use of granules of biphasic ceramic in
rehabilitation of canal wall down mastoidectomy,” European
6 BioMed Research International
Archives of Oto-Rhino-Laryngology, vol. 271, no. 1, pp. 59–64,
2014.
[30] D. Bernardeschi, Y. Nguyen, M. Smail et al., “Middle ear and
mastoid obliteration for cochlear implant in adults: indications
and anatomical results,”Otology and Neurotology, vol. 36, no. 4,
pp. 604–609, 2015.
[31] T. Palva, “Operative technique in mastoid obliteration,” Acta
Oto-Laryngologica, vol. 75, no. 2-6, pp. 289–290, 1973.
[32] M. C. Shea Jr., G. Gardner Jr., and M. E. Simpson, “Mastoid
obliteration with bone,” Otolaryngologic Clinics of North Amer-
ica, vol. 5, no. 1, pp. 161–172, 1972.
[33] R. M. Irving, R. F. Gray, and D. A. Moffat, “Bone pate obliter-
ation or revision mastoidectomy: a five-symptom comparative
study,” Clinical Otolaryngology and Allied Sciences, vol. 19, no. 2,
pp. 158–160, 1994.
[34] H. Decher, “Reduction of radical cavities by homologous
cartilage chips,” Laryngologie, Rhinologie, Otologie, vol. 64, no.
8, pp. 423–426, 1985.
[35] P. Montandon, M. Benchaou, and J. P. Guyot, “Modified canal
wall-up mastoidectomy with mastoid obliteration for severe
chronic otitis media,” ORL, vol. 57, no. 4, pp. 198–201, 1995.
[36] S.W. Cho, Y.-B. Cho, andH.-H. Cho, “Mastoid obliterationwith
silicone blocks after canal wall down mastoidectomy,” Clinical
and Experimental Otorhinolaryngology, vol. 5, no. 1, pp. 23–27,
2012.
[37] J. L. Dornhoffer, “Surgical modification of the difficult mastoid
cavity,” Otolaryngology: Head and Neck Surgery, vol. 120, no. 3,
pp. 361–367, 1999.
[38] A. Deveze, C. Rameh,M. S. Puchol, B. Lafont, J.-P. Lavieille, and
J. Magnan, “Rehabilitation of canal wall down mastoidectomy
using a titanium ear canal implant,” Otology and Neurotology,
vol. 31, no. 2, pp. 220–224, 2010.
[39] J. F. Keating and M. M. McQueen, “Substitutes for autologous
bone graft in orthopaedic trauma,”The Journal of Bone and Joint
Surgery—British Volume, vol. 83, no. 1, pp. 3–8, 2001.
[40] C. G. Finkemeier, “Bone-grafting and bone-graft substitutes,”
The Journal of Bone& Joint Surgery—American Volume, vol. 84,
no. 3, pp. 454–464, 2002.
[41] G. Daculsi, P. Corlieu, M. B. D’Arc, andM. Gersdorff, “Macrop-
orous biphasic calcium phosphate efficiency in mastoid cavity
obliteration: experimental and clinical findings,” Annals of
Otology, Rhinology and Laryngology, vol. 101, no. 8, pp. 669–674,
1992.
[42] M. Bagot D’Arc and G. Daculsi, “Micro macroporous biphasic
ceramics and fibrin sealant as a moldable material for bone
reconstruction in chronic otitis media surgery. A 15 years
experience,” Journal of Materials Science: Materials in Medicine,
vol. 14, no. 3, pp. 229–233, 2003.
[43] M. Bagot d’Arc, G. Daculsi, and N. Emam, “Biphasic ceramics
and fibrin sealant for bone reconstruction in ear surgery,” An-
nals of Otology, Rhinology and Laryngology, vol. 113, no. 9, pp.
711–720, 2004.
Submit your manuscripts at
http://www.hindawi.com
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Corrosion
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Polymer Science
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Ceramics
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Composites
Journal of
Nanoparticles
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Biomaterials
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Nanoscience
Journal of
Textiles
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Journal of
Nanotechnology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Crystallography
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Coatings
Journal of
Advances in 
Materials Science and Engineering
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Smart Materials 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Metallurgy
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Materials
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
N
an
om
at
er
ia
ls
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal ofNanomaterials
